## JNJ: Johnson & Johnson - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 2.2% below STRENGTH zone (3.0-6.0%); PEG 1.07 fails VALUE criteria (<1.0); RSI 72 overbought. Stock is in no-man's land without clear edge. Caution: overbought RSI (72).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($203.21)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 5, Bearish: 0)

**1. Top Research Reports for Broadcom, Exxon Mobil & Johnson & Johnson**
- Source: Yahoo Finance Singapore | 20251210T221135 | Somewhat-Bullish | Relevance: 99%
-  This article highlights Zacks Investment Research's top research reports on 16 major stocks, including Broadcom, Exxon Mobil, and Johnson & Johnson, along with micro-cap companies Investors Title Co. and Friedman Industries. It provides an overview of each company's performance, growth drivers, and challenges, based on analyst insights. The reports detail key financial figures, strategic initiatives, and market conditions impacting these companies.

**2. Dow's 132-point rally led by gains for Johnson & Johnson, Procter & Gamble stocks**
- Source: MSN | 20251209T152020 | Bullish | Relevance: 99%
- The Dow Jones Industrial Average rose by 132 points, driven primarily by strong performances from Johnson & Johnson and Procter & Gamble stocks. This rally indicates positive movement within the industrial average, influenced by these key companies.

**3. ASH: J&J makes case for Tecvayli combo as an alternative to CAR-T in 2nd-line multiple myeloma**
- Source: Fierce Pharma | 20251209T120837 | Bullish | Relevance: 99%
-  Johnson & Johnson presented positive Phase 3 MajesTEC-3 trial data for its Tecvayli-Darzalex combination in multiple myeloma patients, showing an 83% reduction in progression or death risk. This regimen, which significantly improved overall survival, could be a strong alternative to CAR T-cell therapies like J&Jâ€™s own Carvykti, especially for patients who cannot access CAR-T in community settings. The data suggests potential competition for existing CAR-T treatments and highlights J&J's efforts to expand Tecvayli's role in earlier lines of therapy.

**4. Johnson & Johnson (JNJ): Is the 40% Year-to-Date Rally Just Catch-Up to Fair Value?**
- Source: Simply Wall Street | 20251209T011512 | Somewhat-Bullish | Relevance: 99%
- Johnson & Johnson (JNJ) has seen significant momentum, with its stock up 14% in 3 months and nearly 40% year-to-date, prompting questions about its valuation. While the stock trades just below analyst targets, it still shows a substantial intrinsic value gap, suggesting it may be undervalued. However, ongoing talc litigation and revenue pressures from key exclusivity losses pose risks to sustained multiple expansion.

**5. Johnson & Johnson (JNJ) Stock on December 10, 2025: Pipeline Breakthroughs, Talc Risks and What Analysts Expect Next**
- Source: ts2.tech | 20251210T180758 | Somewhat-Bullish | Relevance: 99%
-  Johnson & Johnson's (JNJ) stock is trading near record highs, driven by strong growth in oncology and immunology, especially new data on its multiple myeloma treatments Tecvayli and Carvykti, and the potential blockbuster drug icotrokinra. However, the company faces significant challenges from ongoing talc litigation, with over 90,000 lawsuits and no global settlement in sight. Analysts have a "Moderate Buy" consensus, with price targets close to current trading levels, while some valuation models suggest the stock is still undervalued despite its 2025 rally.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 4, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-11 | Citigroup | $232 | $215 | +8% |
| 2025-12-11 | RBC Capital | $230 | $209 | +10% |
| 2025-12-05 | Guggenheim | $227 | $206 | +10% |
| 2025-12-02 | Barclays | $197 | $176 | +12% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-11 | Citigroup | main | Buy |
| 2025-12-11 | RBC Capital | main | Outperform |
| 2025-12-05 | Guggenheim | main | Buy |
| 2025-12-02 | Barclays | main | Equal-Weight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 1 ($0.26M) |
| Sells | 7 ($4.07M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 36.8% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 5 |

**Top Holders:**
- Vanguard Group Inc: 9.8% (-0.2%)
- Blackrock Inc.: 8.6% (+1.7%)
- State Street Corpora: 5.5% (-0.4%)
- JPMORGAN CHASE & CO: 4.9% (+109.0%)
- Geode Capital Manage: 2.3% (-7.2%)

### Key Risks

1. Insider selling cluster: $4.1M in recent transactions.
2. Overbought RSI (72) with bearish MACD signals exhaustion.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- Analyst target momentum: 4 raises (avg +10%) could attract flows.
- AI/machine learning initiatives could drive multiple expansion if executed.
- Momentum building: MRS_10 improving +5.3% over 5 days suggests accumulation.

### Fundamentals

PEG ratio 1.07 suggests fair value with growth premium. Forward P/E 18.2x stretched relative to 6% growth. Quality metrics strong (ROE 34%, margin 27%). Balance sheet: $8.4B free cash flow. Analyst sentiment positive (4 raises, avg +10%). Insider selling cluster ($4.1M in 90 days), potential headwind. Institutional flow bullish (4 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $506.0B |
| Beta | 0.35 |
| 52W Range | $140.68 - $211.23 |
| Short Interest | 1.0% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.07 |
| Forward P/E | 18.2 |
| Current P/E | 19.3 |
| YoY Growth | 6.1% |
| EPS Direction | STABLE |

### Technicals

MRS_10 strengthening from -3.1% to 2.2% (+5.3% in 5 days), confirming momentum buildup. Below STRENGTH zone by 0.8pp (needs >3.0% for momentum thesis). MRS_5 at 2.9% confirms short-term momentum alignment. Outperforming sector by 4.5pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). RSI overbought at 72, risk of mean reversion.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 2.24% (CS: 63) | Neutral |
| RSI_14 | 71.5 | Overbought |
| MACD Histogram | -0.24 | Bearish |
| vs SMA20 | 1.033x | Above |
| vs SMA50 | 1.076x | Above |
| vs SMA200 | 1.227x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $210.01
- **Stop Loss:** $203.21 (3.2% risk)
- **Target:** $216.81 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 202
- **Position Value:** $42,422.02
- **Portfolio %:** 42.42%
- **Risk Dollars:** $1,380.00
- **Risk Per Trade:** 1.38%
- **Modifiers:** L1 115% | L2 120% | Combined 1.38x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.15x |
| L2 Sector | IGNITION (Zone D) | 1.20x |

*NORMAL regime with moderate risk appetite ahead of Fed decision. VIX at low 8th percentile signals complacency, but decent breadth and positive yield curve support selective positioning. Focus on quality names with earnings visibility.*

### Earnings

**Next:** 2026-01-21 (Est: $2.53)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.76 | $2.80 | +1.5% |
| 2025Q2 | $2.68 | $2.77 | +3.2% |
| 2025Q1 | $2.58 | $2.77 | +7.4% |
| 2024Q4 | $2.01 | $2.04 | +1.4% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*